Obesity Pharmacotherapy
Cross-source consensus on Obesity Pharmacotherapy from 2 sources and 9 claims.
2 sources · 9 claims
Uses
How it works
Risks & contraindications
Comparisons
Background
Highlighted claims
- The 2026 EASO update refines a framework for pharmacological treatment of obesity and obesity-related complications. — Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update
- The update revises an existing treatment algorithm rather than introducing obesity pharmacotherapy as a new concept. — Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update
- The pharmacological treatment framework is intended to guide structured decisions based on patient characteristics, goals, complications, and comparative evidence. — Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update
- Sustained therapy is considered important for preserving reduced body weight and cardiometabolic improvements. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- The strongest refinements in the update concern weight loss and liver disease. — Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update
- Weight regain can reverse cardiometabolic improvements and worsen physical and psychological burden. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- During weight maintenance, reduced energy expenditure and increased energy efficiency lower caloric needs and make regain more likely. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- The findings support continued pharmacotherapy for people who have lost weight with obesity medications. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- The trial argues against the misconception that obesity medications can simply be stopped after weight loss. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial